To Our Valued Wefunder Community,
The response to our mission has been nothing short of inspiring!
Over 500 investors have helped us raise $1 million, making Eliaz Therapeutics one of the top trending companies on Wefunder.
Following this incredible momentum—and our recent FDA Breakthrough Device Designation for XGal-3®—Wefunder has approved one final extension of our early-bird terms to the first $1.2M raised.
This extension honors the remarkable support from our investor community, including 36 investors who increased their stakes by a combined $120K.
For existing investors: This is your last chance to increase your ownership at the favorable $39.6M valuation cap and 10% discount before these terms are permanently closed.
For new investors: Once we reach $1.2M, the valuation increases to $49.5M. Don’t miss this limited opportunity to join our fight against sepsis while securing maximum ownership potential.
Every 2.8 seconds, someone loses their life to sepsis. Together, we have the potential to save millions while disrupting a $39B market.
In faith and determination,
The Eliaz Therapeutics Team
